Indefinite Delivery Contract SPE2DB25D9177

The Department of Defense (DoD) has awarded DMS Pharmaceutical Group Inc., a woman-owned small business, a single-award Indefinite Delivery Contract (IDC) under the SPE2DB program with the Defense Logistics Agency (DLA). The $499,999,999 IDC, valid through November 2026, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide.

The IDC covers an extensive portfolio of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various categories such as injections, tablets, creams, auto-injectors, and specialty medications. This positions DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain, providing direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites. The contract is not associated with any set-aside designations, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains.